FirebrickPharma

7 August 2023

ASX Announcement

Firebrick Covid-19 Trial Achieves Primary Endpoint

- **Nasodine significantly reduced viral shedding versus placebo, achieving the primary endpoint of the trial**
- **100% of Nasodine subjects cleared the virus after completion of treatment**

Firebrick Pharma Limited (ASX:FRE) (**Firebrick, Company**) is pleased to announce that its Phase 2 trial of Nasodine® Nasal Spray ("Nasodine") in COVID-19 achieved its primary endpoint.

The primary endpoint was the reduction in viral load of SARS-CoV-2 over 4 days, based on culturable virus from throat and nasal swabs. Nasodine treatment resulted in 100% reduction by day 4, compared with 48% for placebo and this difference was statistically significant (p=0.028).

"To put this in perspective, the treatment regimen ran over two and a half days and then on the fourth day, 100% of the Nasodine subjects were clear of virus," said Firebrick Executive Chairman, Dr Peter Molloy.

As previously reported (ASX announcement 3 April 2023), the study, which was conducted in South Africa, recruited 39 subjects, 23 of whom were culture-positive and qualified for the primary endpoint population.

"Achieving statistically significant results in viral shedding, in spite of the small number of subjects, is what we hoped for, and Nasodine did not disappoint," said Dr Molloy.

"It shows that Nasodine emphatically reduces viral shedding in a clinical setting. This is an important finding that extends the body of evidence about Nasodine's mechanism of action in treating upper respiratory infections," added Dr Molloy.

The small number of subjects meant that it was not possible to detect statistically significant outcomes on the secondary endpoints, which included the impact on COVID symptoms and the number of days to a RAT-negative test, assessed over five days from start of treatment.

"While COVID-19 may be behind us, it will not be the last global pandemic," said Professor Peter Friedland, the Company's Chief Medical Officer. "A nasal spray that can rapidly clear pandemic viruses from the nasal passages could be extremely valuable in protecting frontline healthcare workers in the next pandemic."

The Company is not planning further COVID-19 studies or intending to pursue regulatory approval for Nasodine use in COVID-19. However, it expects to continue to undertake research that extends the evidence for Nasodine as a therapeutic intervention for upper respiratory infections, especially the common cold.

“Our focus remains on Nasodine as a treatment for the common cold,” said Dr Molloy. “In that regard, we look forward to closing our current Phase 3 trial and announcing the results this quarter.”

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman, Firebrick Pharma Limited.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick is a pharmaceutical company founded in 2012 with the mission to develop and commercialise a nasal spray treatment for the common cold based around the potential of povidone-iodine as a broad-spectrum antimicrobial agent. The Company owns numerous granted and pending patents, including a core patent family that covers the use of intranasal povidone-iodine for the treatment and prevention of the common cold. Firebrick has conducted multiple human clinical trials on Nasodine and is currently completing a second Phase 3 trial to confirm its efficacy as a treatment for the common cold and support international partnering and approvals.

Media enquiries:
Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

Investor enquiries:
Investors@firebrickpharma.com